• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    SC 13G/A 1 armistice-alur093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Allurion Technologies, Inc.

    (Name of Issuer)

     

    Common Stock, par value, $0.0001 per share

    (Title of Class of Securities)

     

    02008G102

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  02008G102
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    7,806,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    7,806,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    7,806,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    12.13%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  02008G102
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    7,806,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    7,806,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    7,806,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    12.13%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 02008G102
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Allurion Technologies, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    11 Huron Drive

    Natick, MA 01760

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value, $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    02008G102

     

    CUSIP No.  02008G102
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 02008G102
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 7,806,000

    Steven Boyd - 7,806,000   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 12.13%

    Steven Boyd - 12.13% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 7,806,000

    Steven Boyd - 7,806,000  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 7,806,000

    Steven Boyd - 7,806,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 64,348,508 Shares outstanding as of August 9, 2024, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 02008G102
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 02008G102
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    SEC Filings

    See more
    • SEC Form S-8 filed by Allurion Technologies Inc.

      S-8 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      6/18/25 5:10:21 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:04:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:02:23 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/17/25 6:36:58 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

      Fourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to responder rate at 48 weeks. Allurion Balloon su

      7/7/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

      Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

      6/17/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Present at Jefferies Global Healthcare Conference

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

      5/29/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allurion Technologies downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

      11/14/24 8:29:33 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • TD Cowen initiated coverage on Allurion Technologies with a new price target

      TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      10/2/24 7:13:57 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • ROTH MKM initiated coverage on Allurion Technologies with a new price target

      ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      9/6/24 7:25:38 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

      Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

      9/3/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

      Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

      8/20/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

      Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

      6/5/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:43:43 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:15:52 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

      SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      10/24/24 5:19:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Financials

    Live finance-specific insights

    See more
    • Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

      5/14/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

      5/5/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

      3/26/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care